1. Repositório Institucional UFC
2. FAMED - Faculdade de Medicina
3. DMC - Departamento de Medicina Clínica
4. DMC - Artigos publicados em revistas científicas

Tipo:	Artigo de Periódico
Título:	Efficacy, safety and tolerability of aripiprazole in bipolar disorder : an updated systematic review and meta-analysis of randomized controlled trials
Autor(es):	Li, Dian-Jeng Tseng, Ping-Tao Stubbs, Brendon Chu, Che-Sheng Chang, Han-Yung Vieta, Eduard Fornaro, Michele Carvalho, Andre F. Solmi, Marco Veronese, Nicola Chen, Tien-Yu Chen, Yen-Wen Lin, Pao-Yen Chows, Philip Chik-keung
Palavras-chave:	Bipolar disorder;Transtorno Bipolar;Aripiprazol
Data do documento:	Out-2017
Instituição/Editor/Publicador:	Progress in Neuropsychopharmacology & Biological Psychiatry
Citação:	LI, DIAN-JENG et al. Efficacy, safety and tolerability of aripiprazole in bipolar disorder : an updated systematic review and meta-analysis of randomized controlled trials. Progress in Neuro-Psychopharmacology & Biological Psychiatry, v. 79, p. 289-301, oct. 2017.
Resumo:	Numerous studies have investigated aripiprazole as a treatment for bipolar disorder (BD). therefore we conducted this comprehensive meta-analysis to investigate the efficacy and safety profile of aripiprazole in treating BD. Two authors conducted systematic searches of PubMed and ScienceDirect from inception until May 14th, 2017. Randomized controlled trials (RCTs) of people with BD who received aripiprazole were included. A total of 20 RCTs met the eligibility criteria, including two which investigated the efficacy of aripiprazole versus haloperidol (aripiprazole =340; haloperidol =337), three which compared aripiprazole versus lithium (aripiprazole =208; lithium =212), and 15 with multiple comparisons of aripiprazole versus a placebo (aripiprazole =1923; placebo =1499). Compared to a placebo, aripiprazole improved acute mania (Hedges' g: −0.299, p=0.001) and psychosis (Hedges' g: −0.296, p < 0.001) in the acute mania state, but did not improve depressive symptoms (Hedges' g: −0.127, p =0.054) in the acute depressive state. Aripiprazole was associated with lower relapse rates in bipolar mania when used in combination versus a placebo in maintenance therapy (odds ratio: 0.522, p < 0.029). Aripiprazole was also associated with higher levels of high density lipoprotein, lower dropout rates, but no difference in extrapyramidal symptoms in the maintenance phase versus a placebo or in comparison with other medications (haloperidol or lithium). Our results suggest that aripiprazole is effective and safe in treating bipolar mania. Further trials are necessary to evaluate the efficacy and tolerability versus other medications.
URI:	http://www.repositorio.ufc.br/handle/riufc/25130
ISSN:	0278-5846
Aparece nas coleções:	DMC - Artigos publicados em revistas científicas

Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.